

## 弁膜症を伴う残存肺高血圧症に対するシルデナフィルの効果は不良(LBCT Session, Abstract 3815)

SIOVAC: 弁膜症を伴う残存肺高血圧症においてシルデナフィルの使用は避けるべきである

SIOVAC: Sildenafil should be avoided in valve disease with residual pulmonary hypertension

弁膜症を伴う残存肺高血圧症患者の治療においてシルデナフィルは使用すべきではない、とのSIOVAC試験の結果が2017 ESC Congress で発表された。この薬剤のオフラベル使用は、プラセボに比べ入院リスクを倍にするなどのより不良な臨床転帰を招いた。6か月後に、シルデナフィルを内服した患者の33% およびプラセボを内服した患者の15%において、臨床複合スコアがスタディ開始時よりも悪化した(改善のオッズ比0.39;  $p < 0.001$ )。主要な臨床イベントは、シルデナフィル群においてより早期かつより高頻度に発現した( $p = 0.044$ )。

### Full Text

Sildenafil should not be used to treat residual hypertension in patients with valvular heart disease, according to late-breaking results from the SIOVAC trial presented today in a Hot Line LBCT Session at ESC Congress. The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalization compared to placebo.

"Valvular disease is considered the next cardiac epidemic because of its strong association with age and the rapid aging of the population worldwide," said principal investigator Dr. Javier Bermejo, a cardiologist at Hospital General Universitario Gregorio Marañón, Madrid, Spain.

"The only established treatment is repair or replacement of the valve surgically or percutaneously," he continued. "But symptoms often remain or reappear in the long-term. Residual pulmonary hypertension is the most important risk factor for death and disability after successful correction of the valvular lesion."

Sildenafil is a potent vasodilator with a strong effect on blood flow. Typically used to treat erectile dysfunction, the drug is also useful for pulmonary hypertension but clinical trials have shown discrepant results in pulmonary hypertension with a retrograde origin. Sildenafil is believed to be safe and well tolerated and is frequently prescribed as an off-label indication in patients with retrograde pulmonary hypertension.

The SIOVAC trial tested the potential of sildenafil to improve long-term outcomes of patients with residual pulmonary hypertension after correction of a valvular lesion. The trial was conducted in 17 public hospitals and coordinated by the Spanish Network Centre for Cardiovascular Research (CIBERCV).

A total of 200 patients were randomized to sildenafil (40 mg three times a day) or placebo for six months. Patients and investigators were blinded to the treatment. Prior to enrollment, patients were screened for contraindications to sildenafil and a catheterization procedure was performed to confirm elevated pressure in the pulmonary artery.

The primary endpoint was a clinical composite score of all-cause death, hospital admission for heart failure, worsening exercise tolerance, and feeling worse than when starting the medication (assessed by change in a self-assessment score).

Contrary to the expected findings, clinical outcomes were worse in the sildenafil group compared to placebo. At six months, 33 (33%) patients taking sildenafil and 14 (15%) taking placebo had a worse composite clinical score than at the start of the study (odds ratio for improvement, 0.39; 95% confidence interval [CI], 0.22 to 0.67;  $p < 0.001$ ).

Dr. Bermejo said: "Compared to patients taking placebo, the chance for worse clinical outcomes — as defined by the combined clinical score — was more than twice as high in those taking sildenafil. We were unable to identify any particular subset of patients who could potentially benefit from sildenafil."

Patients taking sildenafil suffered more, and more frequent, hospital admissions due to heart failure decompensations. In fact, the overall risk for hospital admission was double in patients taking the drug. Three patients taking sildenafil and two patients taking placebo died during the study ( $p = 0.63$ ). Major clinical events — death or readmission due to heart failure — occurred earlier and more frequently in the sildenafil group (hazard ratio, 2.0; 95% CI, 1.0 to 4.0;  $p = 0.044$ ).

"We were surprised to find that decompensations requiring hospital admission were more frequent in patients taking sildenafil," said Dr. Bermejo.

"This is the first clinical trial focused on this complication," he continued. "We found that in patients with residual pulmonary hypertension after successfully corrected valvular heart disease, six-month treatment with sildenafil leads to worse clinical outcomes than placebo."

Dr. Bermejo concluded: "Long-term usage of sildenafil for treating residual pulmonary hypertension in patients with valvular heart disease should be avoided. The high incidence of events during the trial emphasizes the need for further research to prevent and treat this complication in patients with valvular disease."

The study was entirely funded by the Spanish Ministries of Health and Economy in an open call for investigator-driven clinical trials.

## Conference News

### [News 01]

炎症を軽減することにより心血管系および肺がんのリスクが低下する

### [News 02]

早期のリスクファクター介入は洞調律を維持する

### [News 03]

LDLがどのように低下したかが重要

### [News 04]

リパーロキサパンは心血管系および下肢のイベントを減少させる

### [News 05]

塩分の過剰摂取は心不全リスクを倍増させる

### [News 06]

短期間の抗血小板薬2剤併用療法は長期にわたり有効性を保つ

### [News 07]

病院到着前の抗血小板療法の利点はない

### [News 08]

PCIにおける最良の抗血小板薬2剤併用療法に疑問が投げかけられた

### [News 09]

急性MIにおける酸素補充の死亡率に対する有益性はない

### [News 10]

BMI低値はPCI後の予後不良につながる

### [News 11]

黄砂と急性心筋梗塞

### [News 12]

糖尿病性網膜症における強化スタチン療法の有益性に疑問が投げ掛けられた

### [News 13]

トライアルの結果が腎除神経術の論議を再開させる

### [News 14]

InclisiranはLDLコレステロールを最長1年間低下させる

### [News 15]

睡眠の質の低下は心血管疾患につながる可能性がある

### [News 16]

TAVIは90歳超の患者において安全かつ有効である

### [News 17]

弁膜症を伴う残存肺高血圧症に対するシルデナフィルの効果は不良

### [News 18]

高コレステロールは乳がんにおける死亡リスクを低下させる